Castle Biosciences Inc represents values such as innovation, accuracy, and patient-centricity. With a strong corporate philosophy centered around precision medicine, the company utilizes advanced genomic technology to provide actionable, personalized information to aid healthcare decisions for patients with underserved cancers. Castle Biosciences Inc is committed to improving patient outcomes through its proprietary diagnostic tests that offer valuable insights into the individual biology of each patient. By combining science, research, and a patient-first approach, Castle Biosciences Inc strives to empower healthcare providers and patients with the necessary tools to make informed, targeted treatment decisions.

Castle Biosciences Inc is primarily present in the United States.

Castle Biosciences Inc has achieved several significant milestones since its inception. The company pioneered the development of DecisionDx®-Melanoma, a groundbreaking gene expression profile test, which has revolutionized the management of melanoma patients. Castle Biosciences Inc has also expanded its product portfolio with DecisionDx®-UM, a test for uveal melanoma, providing accurate prognostic information for physicians and patients. In addition, the company has received numerous awards and recognitions for its innovative approach to personalized medicine, further establishing its leadership in the field. Castle Biosciences Inc continues to drive advancements in genomic diagnostics, improving patient outcomes and transforming cancer care.

Castle Biosciences Inc is a leading precision oncology company that specializes in molecular diagnostics. Established in 2008, the company is dedicated to providing personalized medicine solutions for patients with challenging cancers. With a focus on dermatologic cancers, Castle Biosciences utilizes advanced genomic and proteomic technology to develop innovative diagnostic tests. Their flagship product, DecisionDx-Melanoma, is a powerful tool that assesses the risk and prognosis of melanoma patients. Castle Biosciences Inc has a strong commitment to research, collaboration, and improving patient outcomes. With their cutting-edge technology and expertise, the company continues to revolutionize cancer diagnostics and treatment strategies.

The main competitors of Castle Biosciences Inc in the market are Myriad Genetics, Genomic Health, and NanoString Technologies.

Castle Biosciences Inc is primarily active in the healthcare industry, specifically in the field of precision medicine. The company specializes in developing and commercializing molecular diagnostics tests that provide personalized genomic information to aid in the diagnosis and treatment of various types of cancer. Castle Biosciences Inc's innovative solutions help healthcare professionals make informed decisions about patient care by assessing the likelihood of disease recurrence and determining optimal treatment plans. With a focus on improving patient outcomes, Castle Biosciences Inc is dedicated to advancing precision medicine in oncology.

The business model of Castle Biosciences Inc revolves around providing diagnostic and prognostic solutions for patients with skin and other cancers. By leveraging advanced genomic technology, the company offers diagnostic tests that assess the risk, recurrence, and progression of various cancers. Castle Biosciences focuses on developing and commercializing molecular diagnostic tests that aid in personalized treatment decisions for cancer patients. With a patient-centric approach, the company aims to improve patient outcomes and contribute to the advancement of precision medicine. Castle Biosciences Inc is dedicated to revolutionizing cancer management through innovative diagnostics.

Коефициентът на цена спрямо печалбата (КЦП) на Castle Biosciences е -16,24.

Коефициентът на цена към оборот (KUV) на Castle Biosciences е 2,78.

AlleAktien качественият резултат за Castle Biosciences е 4/10.

очаквана Castle Biosciences оборотът е 265,60 млн. USD.

очаквана Castle Biosciences печалба е -45,45 млн. USD.

Castle Biosciences Inc is a biotechnology company that develops and distributes diagnostic tests and genetic analyses. The company is headquartered in Friendswood, Texas, USA and has been operating in the industry since 2007. The main task of Castle Biosciences is to develop clinically accurate prediction tools to assess the progression of tumors and consider them in patient treatment. For this purpose, the company has developed a range of test procedures based on a combination of genotyping, proteomics, and immuno-sensing methods. The key product of Castle Biosciences is the Prognostic Test, which provides an accurate assessment of the risk of skin cancer. The test uses molecular markers to predict the risk of melanoma or ocular melanoma and determine if therapy is necessary. Another product is DecisionDx-UM, a powerful diagnostic assay that aids in the prognosis of malignant uveal melanoma (UM). In combination with standardized clinical factors such as age, gender, and tumor size, DecisionDx-UM is an important indicator of disease progression as well as promising treatment approaches. Castle Biosciences offers a wide range of proteomic analyses tailored to the needs of the patient. These tests are used to estimate the risk of cancer and enable treating physicians to develop treatment and follow-up strategies. The company also conducts a number of research and development initiatives aimed at understanding the molecular basis of cancer and developing novel diagnostic tests and therapies. The goal is to make groundbreaking scientific discoveries to identify new and improved molecular markers that can be used to assess disease progression and the efficacy of therapies. Overall, Castle Biosciences provides an advanced and accurate platform for cancer diagnostics that can help patients and doctors make better-informed decisions. The company is dedicated to further exploring the molecular basis of cancer and developing more innovative diagnostic tools to improve patient care worldwide. In summary, the business model of Castle Biosciences is focused on the development and marketing of diagnostic tools for cancer treatment. The company offers a wide range of molecular, proteomic, and immuno-sensing analyses that enable accurate prognosis of tumor progression. The company also conducts extensive research and development initiatives to discover new molecular markers for the diagnosis and treatment of cancer.

Castle Biosciences разпределя дивидента от 0 USD на плащания годишно.

Дивидентата за Castle Biosciences в момента не може да бъде изчислена или компанията не разпределя дивиденти.

ISIN на Castle Biosciences е US14843C1053.

WKN на Castle Biosciences е A2PNH3.

Тикерът на Castle Biosciences е CSTL.

През последните 12 месеца Castle Biosciences изплати дивиденда в размер на . Това съответства на дивидендна доходност от около . За следващите 12 месеца се очаква Castle Biosciences да изплати дивиденда в размер на 0 USD.

Дивидентната доходност на Castle Biosciences в момента е .

Castle Biosciences изплаща дивидент на тримесечие. Той се разпределя в месеците .

Castle Biosciences платеше дивиденда всяка година през последните 0 години.

За идните 12 месеца се очакват дивиденти в размер на 0 USD. Това съответства на дивидентна доходност от 0 %.

Castle Biosciences се отнася за сектор 'Здраве'.

За да получите последното дивидентно плащане от Castle Biosciences на 23.08.2024 г. в размер на 0 USD, трябваше да притежавате акцията в портфейла си преди Ex-деня на 23.08.2024 г..

Последното дивидентно плащане беше извършено на 23.08.2024 г..

През година 2023 Castle Biosciences изплати 0 USD под формата на дивиденти.

Дивидентите от Castle Biosciences се изплащат в USD.